Skip to main
CRBU

Caribou Biosciences (CRBU) Stock Forecast & Price Target

Caribou Biosciences (CRBU) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Caribou Biosciences is expected to continue to see improvements in their financial results, with a net loss of $0.26 per share in 1Q26 compared to a previously estimated net loss of $0.32 per share. They also have a healthy balance sheet with $118.6M in cash, cash equivalents, and marketable securities, providing a strong runway into the second half of 2027. Additionally, the company's discounted cash flow valuation, combined with a high probability of approval for their lead assets, CB-010 and CB-011, leads to a positive outlook for their future growth potential. However, there are some risks to consider, such as the potential for negative clinical results or delays in advancing candidates into registrational programs.

Bears say

Caribou Biosciences is facing significant challenges in its CRISPR genome-editing technology and has reported a negative net income of $28.7 million for the second quarter of 2021. The company has also reported a decrease in its collaboration revenue from $4.1 million in the second quarter of 2020 to $0.7 million in the same period of 2021. Additionally, the company is heavily reliant on the United States for revenue, which exposes it to potential regulatory hurdles and market volatility.

Caribou Biosciences (CRBU) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Caribou Biosciences (CRBU) Forecast

Analysts have given Caribou Biosciences (CRBU) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Caribou Biosciences (CRBU) has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Caribou Biosciences (CRBU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.